Integrated Plasma Proteomics and Functional Analyses Reveal Hepatic CDHR2 as a Potential Therapeutic Target in MASLD - PubMed
3 days ago
- #therapeutic target
- #CDHR2
- #MASLD
- The study identifies CDHR2 as a potential therapeutic target for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Integrated plasma proteomics and functional analyses were used to identify proteins associated with MASLD, with CDHR2 showing significant causal associations.
- Genetically predicted higher levels of CDHR2 were linked to increased risks of both MASLD and liver cirrhosis.
- CDHR2 was found to be up-regulated in hepatocytes of MASLD patients compared to healthy controls.
- In vitro experiments demonstrated that CDHR2 knockdown reduced adipogenesis and enhanced antioxidant responses in steatotic hepatocytes.
- The findings suggest CDHR2 plays a critical role in MASLD development and progression, highlighting its therapeutic potential.